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A Bayesian path analysis to
estimate causal effects of
bazedoxifene acetate on
incidence of vertebral fractures,
either directly or through
non-linear changes in bone mass density
J Detilleux,1 J-Y Reginster,1 A Chines2 and O Bruye`re1
Abstract
Background/Aims: Bone mass density values have been related with risk of vertebral fractures in post-
menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture,
which decreases its usefulness as a surrogate in clinical trials. We propose a modeling framework with
three interconnected parts to improve the evaluation of bone mass density accuracy in forecasting
fractures after treatment.
Methods: The modeling framework includes: (1) a piecewise regression to describe non-linear temporal
BMD changes more accurately than crude percent changes, (2) a structural equation model to analyze
interdependencies among vertebral fractures and their potential risk factors in preference to regression
techniques that consider only directional associations, and (3) a counterfactual causal interpretation of the
direct and indirect relationships between treatment and occurrence of vertebral fractures. We apply the
methods to BMD repeated measurements from a study of the effect of bazedoxifene acetate on incident
vertebral fractures in three different geographical regions.
Results:We made four observations: (1) bone mass density changes varied largely across participants, (2)
baseline age and body mass index influenced baseline bone mass density that, in turn, had an effect on
prevalent fractures, (3) direct and/or indirect effects of bazedoxifene acetate on incident fractures were
different across regions, and (4) estimates of indirect effects were sensible to the presence of post-
treatment unmeasured confounders. In one region, around 40% of the bazedoxifene acetate effect on
the occurrence of fracture is explained by its effect on bone mass density. Under the counterfactual
approach, these 40% represent the average difference in the occurrence of fracture observed for
untreated individuals when their bone mass density values are set at the value under bazedoxifene
acetate versus under placebo.
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Conclusions: Computational methods are available to evaluate and interpret the surrogacytic capability
of a biomarker of a primary outcome.
Keywords
Causal analysis, structural equation model, piecewise regression, bone mineral density, vertebral fracture,
bazedoxifene acetate
1 Introduction
Vertebral fracture in post-menopausal women is a serious public health issue. In 2000, there were an
estimated 9 million new osteoporotic fractures, of which 1.4 million were clinical vertebral fractures.
As much as 51% of all these fractures are found in Europe and the Americas.1 Many factors are
known to increase the risk for vertebral fractures in post-menopausal women, among which
decreased bone mineral density (BMD), advanced age, preexisting vertebral fractures, early
menopause, ethnicities, current smoking and maternal fracture history.2,3
Values of BMD, measured either at a single point in time4 or as percent changes across time5 have
been related with the risk of fracture. The risk of multiple vertebral fractures in post-menopausal
women increased by 2.1 (95% CI: 1.2–3.9) and 2.4 (95% CI: 1.34.3) for each standard deviation
decrease in BMD measured by dual-energy X-ray absorptiometry (DXA) lumbar spine and DXA
total hip, respectively.6 Values of BMD have also been associated with bone stiﬀness and strength7
and with vertebral mechanical behavior.8 Because of these properties, BMD measurements have
been incorporated in the WHO Fracture Risk Assessment Tool (FRAX) to estimate 10-year
probability of osteoporotic fracture.9
However, BMD is not perfectly accurate in predicting risk of fracture. There is no exact BMD
cut-oﬀ point to characterize absolutely a person who will fracture from one who will not. A meta-
analysis of treatment osteoporosis trials revealed that increased spinal BMD accounted for less than
25% of the overall reduction in fracture risk.10 Others observed that the proportion of fracture risk
reduction explained by BMD change is around 4% for raloxifene, varies from 16% to 28% for
bisphosphonates11 and up to 75% for strontium ranelate.5 Such proportions, often called
proportions of treatment eﬀect explained by a surrogate (PTE), are typically obtained as the ratio
of regression coeﬃcients for the treatment eﬀect on fracture risk from models with or without the
surrogate.12,13 Unfortunately, the PTE is variable and can fall outside the allowed range [0, 1] for a
proportion. Also, models do not allow for an interaction between biomarker and treatment, and
there is no guarantee they both ﬁt equally well the data.14,15
In this study, we propose a modeling framework with three interconnected parts to evaluate
BMD accuracy in forecasting fractures after treatment. Treatment is bazedoxifene acetate (BZA),
BMD are measured repeatedly, and fractures are vertebral but the methodology may be applied to
other experiments and drugs.
In the ﬁrst part of the framework (Part 1), we suggest modeling BMD changes after treatment
with piecewise regressions. Traditionally, repeated measures of BMD are synthesized in BMD
percent changes from baseline to a predetermined point in time but BMD temporal changes are
often non-linear across the menopause transition period or after treatment.16 For example, in
post-menopausal women receiving BZA, BMD mean percent changes from baseline increased
linearly until they reached a plateau.11,17 In such a case, percent changes computed between
baseline and a time-point occurring before (or after) the time plateau is reached, is higher (or
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lower) than the real BMD changes observed after taking the drug. Piecewise regression models are
an interesting alternative because they are broken-stick models with two or more lines joined at
breakpoints. The nonlinear trend is constructed out of these linear lines. Slopes for the diﬀerent lines
and breakpoints therefore characterize more correctly BMD ﬂuctuations than percent changes.
In the second part of the framework (Part 2), we propose using structural equation models (SEM)
to explore the web of relationships between treatments, risk of fracture and potential risk factors
among which BMD changes quantiﬁed with piecewise regressions. Usually, eﬀects of treatment and
risk factors on vertebral fractures are identiﬁed by Poisson or logistic regressions.9,18 Such regression
models assume only directional associations between the risk factors and occurrence of vertebral
fractures and ignore all possible inter-relationships. Conversely, SEMs are techniques appropriate to
evaluate complex networks of relationships among variables.19 In SEM, risk factors and treatment
can be both independent and dependent variables so alternative hypotheses can be tested regarding
their direct and indirect (or mediated) relationships with the outcome of interest.20 Here, the
Bayesian approach to SEM is privileged over classical inference methods (e.g. maximum
likelihood, generalized or weighted least squares) because the approach allows the incorporation
of prior knowledge about the parameters and is computationally faster and more tractable
(e.g. singularities in the likelihood surface).
In the third part of the framework (Part 3), we convey counterfactual causal analyses to interpret
the direct and indirect relationships between BMD and vertebral fracture as identiﬁed within the SEM
framework. Usually, candidate surrogates, such as BMD, are evaluated in models that assumed no
sequential ignorability (i.e. no unmeasured confounders of the BMD–fracture relationships such that
BMD is randomly assigned to individuals in addition to the treatment) and no interaction between
eﬀects and treatment status.21 When these assumptions are violated, signiﬁcant associations do not
reﬂect causality.22 Fortunately, both assumptions may be partially released in methods based on
counterfactual experimental conditions in which BMD is theoretically measured on each participant
as if he/she received both treatment and placebo.23,24 In this context, the direct and indirect eﬀect of a
treatment on the risk of fracture is deﬁned as the population mean of individual direct and indirect
eﬀects. An individual direct eﬀect is the diﬀerence between fracture occurrence when an individual is
treated and BMD is set at its value under treatment, and fracture occurrence when the same individual
is not treated. An individual indirect eﬀect is the diﬀerence between occurrence of fracture when an
individual is untreated and BMD is set at its value under treatment, and occurrence fracture when
BMD of the same individual is set at its value under placebo.25
2 Subjects and methods
Data on 3776 Caucasian post-menopausal women (age 50–85) were retrieved from a 3-year,
randomized, double-blind, placebo- and active-controlled study, healthy postmenopausal women
with osteoporosis. Femoral neck and total hip BMD were measured by DXA at baseline, 6, 12, 18,
24 and 36 months, or at early termination in subjects who withdrew. Vertebral fractures were
diagnosed using both semi-quantitative and quantitative morphometric assessment approaches on
participants at baseline, and once during the follow-up period. Subjects were randomized to receive
BZA (20 or 40mg/day) or placebo. All subjects received oral daily calcium (up to 1200mg) and
vitamin D (400–800 IU) supplementation.26
Analyses concerned 21,134 total hip and 21,166 femoral neck BMD measurements on post-
menopausal women in sites located in three distinct geographical regions (Europe, North and
South Americas). For each ith participant, three dependent variables are considered: the
measure of BMD at time Tt(yit), the binary variable Fi with Fi¼ 1 if the participant presents a
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fracture at baseline, and 0 if not, and the binary variable zi with zi¼ 1 if the participant presents a
fracture during the follow-up period, and 0 if not. The time at which the event occurs is denoted Tt
(Tt¼ 0, 6, 12, 18, 24, 36 months for t¼ 1 to 6) and i¼ 1, 2, . . . , nk patients in the geographical
region k (k¼ 1, 2, 3).
In Part 1, BMD measures are distributed as:
yit  Normal ð1i þ 1iTt, 2i Þ for Tt  Ki
yit  Normal ð2i þ 2iTt, 2i Þ for Tt4Ki:
The lines describe the changes in BMD before and after the breaking point (Ki). Intercepts and
regression coeﬃcients for the lines before (and after) Ki are 1i and 1i (and 2i and 2i), respectively.
Both lines meet at Ki hence the BMD value at Ki is given by: 2i¼Ki(1i –2i)þ1i.
After discussion with experts (authors of the paper) in osteoporosis, the model for the SEM
analyses was set (Part 2). Baseline age and body mass index were considered as potential
predictors of baseline BMD (1i) and treatment of BMD initial increase (1i). In turn, baseline
BMD was tentatively associated with prevalent and incident fractures whereas BMD initial
increase, treatment and prevalent fractures were linked with incident fractures. The corresponding
equations are:
1i  Normalð 0m þ 1mAi þ 2mBi, 2aÞ,
1i  Normalð 0b þ 1bRi, 2bÞ,
Fi  Bernoulli pið Þ; logit pið Þ ¼ g0 þ g11i
zi  Bernoulli qið Þ; logit qið Þ ¼ h0 þ h11i þ h21i þ h3Ri þ h4Fi þ h5ðRÞ1i
where Ai is the age in years of the patient at baseline; Bi is the body mass index (BMI; kg/m
2) of the
patient at baseline; Ri is 1 if the patient received the BZA, and 0 if he/she received a placebo; (R)1i is
the interaction between 1i and Ri. Then, 0m¼ baseline BMD adjusted for age and BMI;
1m¼ linear change in baseline BMD by year increase in age; 2m¼ linear change in baseline
BMD by unit increase in BMI; 0b¼BMD slope for women in the placebo group;
1b¼ diﬀerence in the BMD slope between women receiving BZA versus placebo; g0¼ logit of
prevalent fracture adjusted for 1i; g1¼ linear change in the logit of prevalent fracture by unit
increase in baseline BMD; h0¼ logit of incident fracture adjusted for the eﬀects in the model;
h1¼ linear change in the logit of incident fracture by unit increase in 1i; h2¼ linear change in the
logit of incident fracture by unit increase in 1i; h3¼ diﬀerence in the logit of incident fracture
between subjects receiving BZA versus placebo; h4¼diﬀerence in the logit of incident fracture
between subjects receiving with versus without prevalent fracture; h5¼ linear change in the logit
of incident fracture by unit increase in BMD slope in subject with BZA versus placebo.
In Part 3, a counterfactual approach was used to explicitly formalize the direct and indirect eﬀects
of BZA on occurrence of fracture, based on results from Part 1 and Part 2. To do so, we ﬁrstly deﬁned
0i as the value of the BMD slope (1i) when the subject was assigned to the control group (
0
i ¼ 0b)
and 1i when the subject was assigned to the BZA group (
1
i ¼ 0bþ 1b). Next, we computed four






i ) for each participant: the logit of the probability of fracture when the
participant received the placebo under 0i (
00




i ), and when the participant received
BZA under 0i (
01




i ). Then, average direct () and indirect (	) eﬀects
23,24 were
 ¼ E½11i  10i  ¼ h5ð 0b þ 1bÞ þ h3 and 	 ¼ E½10i  00i  ¼ h11b
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A counterfactual equivalent of the PTE is: E½10i  00i =E½11i  00i . The numerator is the indirect
eﬀect of BZA on incidence of vertebral fracture and the denominator is its total eﬀect, i.e. the
diﬀerence in incident fractures between participants with or without BZA, at the observed levels
of BMD.
Bayesian estimates of all parameters in the framework were obtained after 20 000 MCMC
iteration runs with 2000 iterations burn-in (OpenBUGS30). We chose inverse-gamma priors for




b), normal priors for the coeﬃcients , , , ,
g and h, and truncated normal priors for Ki, which was known in advance to fall within the time
range, i.e. 0 to 36 months. Initial values for the mean and precision of all normal priors were set at 0
and 10–5, respectively, with the exception of the prior means for 0m, h0 and g0 that were obtained
from the data (empirical Bayesian estimates). The initial value of 0m was the observed average
BMD value at baseline (Table 1). The initial values of g0 and h0 were the logit of the average
prevalent and incident fracture rates, respectively.
At the end of all iterations, a sensitivity analysis23 was performed because the assumption of
sequential ignorability (i.e. slopes 1i are randomized across participants) could not be veriﬁed.
Diﬀerent values for the average causal indirect eﬀects were computed for diﬀerent values of the
sensitivity parameter (@) as










where h03 is the regression coeﬃcient of the treatment on logit of zi without adjusting for 1i; @ is the
correlation between error terms in the models for 1i and zi (Part 2); q is the incident rate of fracture;
and s is the standard deviation of 1i. Imai et al.
23 showed @¼ 0 under sequential ignorability and the
magnitude of @ represents the departure from the assumption.
The same framework was applied to each BMD site (femoral neck and total hip) and to
participants in each geographical region, separately. Indeed, geographic variation in vertebral
fracture occurrence has been shown, for example, across regions within Europe and between
South and North Americas.27,28 Risk of vertebral fracture depends also upon the site of BMD
measurement.29
3 Results
Demographic and baseline characteristics can be found in Table 1 for each geographic region.
Baseline BMI ranged from 15 to 38 kg/m2, with an average of 26.5 kg/m2 (SD¼ 3.77). At
baseline, average femoral and total hip BMD were 71.11 g/cm2 (SD¼ 12.30) and 79.92 g/cm2
Table 1. Demographic and baseline characteristics: mean and standard deviation in parentheses
Mean (SD) Region 1 (n¼ 599) Region 2 (n¼ 1850) Region 3 (n¼ 1327)
Age (years) 65.95 (7.44) 66.42 (6.37) 66.23 (6.51)
BMI (kg/m2) 26.57 (4.11) 26.28 (3.62) 26.79 (3.81)
Prevalent fracture (%) 70.78 (45.51) 56.70 (49.56) 45.74 (49.84)
Total hip BMD (cg/cm2) 79.30 (12.27) 80.02 (11.12) 80.04 (11.92)
Neck femoral BMD (cg/cm2) 68.75 (12.84) 71.19 (11.89) 72.07 (12.49)
BMI: body mass index; BMD: bone mass density.
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(SD¼ 11.59), respectively. The prevalent rate of vertebral fracture was 55.97% and 54.64% in the
placebo and BZA groups, respectively. While average BMI and BMD measurements were not
diﬀerent across regions, averages for age and prevalent fracture in region 1 were diﬀerent from
averages observed in the other two regions (test t student; p< 0.01). A description of the non-linear
trend in BMD is given in Figure 1 where crude percent changes from baseline up to 36 months in
total hip (left panel) and femoral neck (right panel) BMD are shown for participants in both groups
and each region. As expected, they were positive in the BZA group with a tendency to increase until
a maximum was reached at which they stabilized before declining slowly. In the placebo groups, they
decreased across time and became negative or close to null in regions 1 and 2 while remaining
positive in region 3.
Bayesian estimates of the parameters of the SEM (Part 2) are given for each region in Table 2 for
total hip BMD, and in Table 3 for femoral neck BMD. Results were similar in both tables and across
the 3 regions, as suggested by the overlapping 95% credibility intervals for all parameters of the
piecewise regression. Looking more closely at hip BMD, we observed average baseline values for hip
BMD (b) close to 80 cg/cm
2 in all regions. No signiﬁcant changes were observed across time (95%
credibility intervals for 0b include 0) in the placebo groups. On the other hand, BMD increased in
participants receiving BZA with a positive slope (95% credibility intervals for 1b greater than 0)
before the break point Ki was reached. The expected time at which the plateau was reached (K) was
close to 29 months. At that time, average percent changes in BMD were estimated at 1.09%, 1.98%
and 1.89% for participants in the BZA group in region 1, 2 and 3, respectively. These values were
obtained from equations in Part 1, using the fact that segmented lines meet at Ki.
Basal hip BMD increased with BMI and decreased with age at baseline. Their eﬀects were
estimated by substituting the values for 1i, which gives logit(pi)¼g0þ g11i¼ g0þ g1(0mþ 1m
Aiþ 2m Bi). Then, the frequencies of prevalent fractures for a woman of 65 years with a BMI of
26 kg/m2 were estimated at 72.67%, 57.15% and 44.95% in region 1, 2 and 3, respectively. Likewise,
the probability of occurrence of a new fracture during the study period was computed as
logit(qi)¼ h0þ h10bþ h2(0mþ 1mAiþ 2mBi) in the placebo group, and logit(qi)¼ h0þ h1
0bþ h2(0mþ 1mAiþ 2mBi) h3þ h11bþ h5(0bþ 1b) in the BZA group. Then, frequencies of
new fractures for a woman with age of 65 years and BMI of 26 kg/m2 were 0.78%, 0.81% and
0.46% in the BZA groups, and 2.11%, 1.36% and 1.84% in placebo groups (regions 1, 2 and 3).
Average direct and indirect eﬀects of BZA on the logit of incident fractures are given in Table 4
for total hip and neck femoral BMD. Eﬀects of BZA on incident vertebral fractures were mostly
direct in region 3 and indirect in region 2 (95% credibility intervals for  and 	 limited by negative
values). In region 1, estimates for both direct and indirect eﬀects showed large variation and were
not signiﬁcantly diﬀerent from null (largest SD). These diﬀerences between regions are illustrated in
Figure 1. Indeed, in region 3, percent changes in BMD had a tendency to increase and remained
positive in both BZA and placebo groups and this suggests BZA did not inﬂuence BMD. Inversely,
in the other two regions, BMD decreased and became negative for participants receiving the
placebo. The counterfactual equivalent of PTE in region 2, where indirect eﬀects were not null,
was estimated at 41.57% for hip BMD and 43.97% for neck femoral BMD (Table 4). Results from
the sensitivity analyses are shown in Figure 2 for hip and neck femoral BMD in the 3 regions. One
can see that estimates of indirect eﬀects varied greatly, with higher departures from the current
estimates of the indirect eﬀects when the sensitivity parameter increased towards its absolute
maximum.
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Figure 1. Average percent changes in total hip (left panel) and neck femoral (right panel) BMD from baseline to 36
months for women receiving BZA (hatched blocks) or placebo (dotted blocks) in the 3 regions. Vertical bars are the
standard errors.
BMD: bone mass density; BZA: bazedoxifene acetate.
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4 Discussion
To our knowledge, this is the ﬁrst attempt to quantify temporal changes in BMD with piecewise
regression and eﬀects of BZA on incidence of vertebral fractures using counterfactual concepts and
structural equations.
Table 2. Bayesian estimates of the parameters of the structural equation model for total hip BMD in the three
regions. Symbols refer to equation (1) in the text
Mean (SD)
Lower and upper bounds of the 95% credibility
intervals Region 1 Region 2 Region 3
Average of expected individual basal BMD
(b¼1i/n)
79.39 (0.45) 80.20 (0.24) 80.42 (0.27)
78.51 to 80.28 79.73 to 80.66 79.89 to 80.96
Expected BMD slope after the break-point (a) 2.99 (5.08) 5.52 (2.76) 5.14 (3.13)
12.92 to 6.94 10.91 to 0.12 11.28 to 1.00
Expected time at the breakpoint (K) 28.65 (3.79) 29.18 (2.27) 28.97 (2.65)
21.19 to 36.06 24.72 to 33.63 23.73 to 34.14
Baseline BMD adjusted for the effects in the
model (0m)
62.30 (4.73) 65.38 (2.95) 71.74 (3.33)
53.01 to 71.57 59.61 to 71.14 65.20 to 78.29
Linear change in baseline BMD by year increase in
BMI (1m)
1.25 (0.11) 1.15 (0.06) 1.54 (0.07)
1.04 to 1.46 1.03 to 1.28 1.40 to 1.68
Linear change in baseline BMD by unit increase in
age (2m)
0.24 (0.06) 0.23 (0.04) 0.49 (0.04)
0.36 to 0.13 0.31 to 0.16 0.57 to 0.41
BMD slope for women in the placebo group
(100*0b)
3.37 (2.54) 0.78 (1.45) 1.71 (1.66)
8.36 to 1.61 2.08 to 3.63 1.55 to 4.95
Difference in the BMD slope between women
receiving BZA vs placebo (100*1b)
7.36 (0.93) 4.66 (0.48) 3.49 (0.66)
4.54 to 8.20 3.73 to 5.60 2.22 to 4.78
Logit of prevalent fracture adjusted for the effects
in the model (g0)
4.10 (0.73) 3.20 (0.38) 3.49 (0.40)
5.59 to 2.71 3.95 to 2.45 4.30 to 2.71
Linear change in the logit of prevalent fracture by
unit increase in baseline BMD (g1)
0.06 (0.01) 0.04 (0.00) 0.04 (0.00)
0.05 to 0.08 0.03 to 0.05 0.03 to 0.05
Logit of incident fracture adjusted for the effects
in the model (h0)
2.62 (3.08) 1.71 (1.23) 0.85 (1.70)
3.44 to 8.65 4.14 to 0.68 4.20 to 2.49
Linear change in the logit of incident fracture by
unit increase in BMD slope (h1)
7.28 (9.41) 7.91 (4.19) 1.92 (4.59)
27.14 to 10.45 16.35 to 1.12 10.96 to 7.13
Linear change in the logit of incident fracture by
unit increase in baseline BMD (h2)
0.08 (0.04) 0.03 (0.02) 0.04 (0.02)
0.17 to 0.01 0.06 to 0.00 0.08 to 0.01
Difference in the in the logit of incident fracture
between subjects receiving BZA vs
placebo (h3)
0.79 (1.17) 0.49 (0.40) 0.95 (0.55)
2.89 to 1.77 1.27 to 0.30 2.08 to 0.19
Difference in the logit of incident fracture
between subjects receiving with vs without
prevalent fracture (h4)
1.44 (0.82) 0.82 (0.37) 0.09 (0.51)
3.15 to 0.08 0.11 to 1.58 0.93 to 1.08
Interaction – Linear change in the logit of incident
fracture by unit increase in BMD slope in
subject with BZA (h5) versus placebo
8.35 (11.79) 6.19 (6.05) 7.13 (7.74)
14.19 to 32.29 5.58 to 18.16 22.45 to 7.95
BMD: bone mass density; BZA: bazedoxifene acetate.
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Piecewise regression models (Part 1) were valuable in this study because BMD values increased
linearly until they reached a plateau in participants receiving BZA (Figure 1). This was also shown
by others.11,17 The time when the plateau was reached and the magnitude of the BMD change were
very diﬀerent across participants. Indeed, credibility intervals observed around the median values
for 1b and k were very large (Tables 2 and 3). This suggests that ﬁxing, for all participants the same
moment at which percent BMD change from baseline should be measured may not be adequate to
Table 3. Bayesian estimates of the parameters of the structural equation model for femoral neck BMD in the three
regions. Symbols refer to equation (1) in the text
Mean (SD)
Lower and upper bounds of
the 95% credibility intervals Region 1 Region 2 Region 3
Average of expected individual basal BMD
(b¼1i/n)
68.80 (0.49) 71.34 (0.27) 72.29 (0.30)
67.82 to 69.76 70.82 to 71.87 71.69 to 72.88
Expected BMD slope after the breakpoint (a) 2.02 (5.05) 3.99 (2.74) 4.07 (3.19)
11.89 to 7.85 9.33 to 1.41 10.43 to 2.12
Expected time at the breakpoint (K) 28.79 (3.79) 29.57 (2.27) 29.54 (2.64)
21.35 to 36.19 25.14 to 34.02 24.36 to 34.74
Baseline BMD adjusted for the effects in the
model (0m)
62.05 (5.16) 58.91 (3.33) 77.51 (3.66)
51.98 to 72.29 52.39 to 65.48 70.36 to 84.71
Linear change in baseline BMD by year increase in
BMI (1m)
0.93 (0.12) 0.78 (0.07) 1.23 (0.08)
0.69 to 1.16 0.64 to 0.93 1.07 to 1.38
Linear change in baseline BMD by unit increase in
age (2m)
0.27 (0.07) 0.12 (0.04) 0.57 (0.05)
0.40 to 0.14 0.20 to 0.04 0.67 to 0.48
BMD slope for women in the placebo group
(100*0b)
2.61 (0.77) 1.27 (0.39) 1.34 (0.50)
4.13 to 1.08 2.03 to 0.50 0.37 to 2.31
Difference in the BMD slope between women
receiving BZA vs placebo (100*1b)
4.55 (0.94) 4.58 (0.48) 3.30 (0.62)
2.70 to 6.39 3.63 to 5.51 2.08 to 4.52
Logit of prevalent fracture adjusted for the effects
in the model (g0)
3.11 (0.60) 2.90 (0.32) 2.72 (0.34)
4.26 to 1.92 3.55 to 2.29 3.36 to 2.04
Linear change in the logit of prevalent fracture by
unit increase in baseline BMD (g1)
0.06 (0.01) 0.04 (0.00) 0.03 (0.00)
0.04 to 0.08 0.04 to 0.05 0.02 to 0.04
Logit of incident fracture adjusted for the effects
in the model (h0)
0.47 (2.43) 1.79 (1.10) 0.68 (1.51)
5.02 to 4.39 3.88 to 0.39 3.53 to 2.51
Linear change in the logit of incident fracture by
unit increase in BMD slope (h1)
3.42 (14.31) 11.16 (5.61) 5.27 (5.76)
23.66 to 33.36 22.87 to 1.65 16.69 to 6.07
Linear change in the logit of incident fracture by
unit increase in baseline BMD (h2)
0.04 (0.04) 0.04 (0.01) 0.05 (0.02)
0.12 to 0.03 0.07 to 0.01 0.09 to 0.00
Difference in the in the logit of incident
fracture between subjects receiving BZA vs
placebo (h3)
1.09 (1.16) 0.48 (0.51) 0.99 (0.58)
3.39 to 1.23 1.44 to 0.58 2.21 to 0.17
Difference in the logit of incident fracture
between subjects with vs without prevalent
fracture (h4)
1.70 (0.85) 0.92 (0.38) 0.11 (0.51)
3.50 to 0.16 0.21 to 1.70 0.90 to 1.09
Interaction – Linear change in the logit of incident
fracture by unit increase in BMD slope in
subject with BZA (h5) vs placebo
1.52 (16.52) 14.06 (7.31) 2.79 (9.99)
34.78 to 31.07 0.01 to 28.61 22.09 to 17.35
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evaluate the eﬃcacy of BZA. A same percent BMD change after a ﬁxed amount of time may indeed
represent BMD value that reached a low plateau before or a high plateau after the ﬁxed time, both
with possible diﬀerent impact on the risk of incident fracture. Note our model was very simple (i.e.
two linear segments with a single join point) and more complex models could improve this and other
settings.
We next proposed a SEM to study the interdependencies between age, BMI, BMD parameters,
and occurrence of vertebral fractures (Part 2). Indeed, SEMs are adequate to model complex
relationships between variables and to study direct and indirect eﬀects of variables on one
another.20 The SEM was based on our current (partial) understanding of the relationships
between variables but other SEMs could also be suggested. For example, we may have
considered baseline age and BMI aﬀect the frequency of incident vertebral fractures, with or
without inﬂuencing BMD. Fortunately, relationships are clearly speciﬁed in SEMs and this
allows transparent understanding and discussion of the results, knowing the assumptions of the
SEM. Here, we observed age decreased and BMI increased baseline BMD. In turn, baseline BMD
had small eﬀects on frequency of baseline and incident vertebral fractures. Prevalent fractures had
no eﬀect on incident fractures, with the exception of region 2. These results were conﬁrmed in
some31–33 but not34,35 previous studies.
In the last part of the study (Part 3), we presented a causal interpretation of the relationship
between BZA, BMD and incident fractures. Understanding causality is a real issue when one has to
judge the worth of a treatment based on its impact on a biomarker. For example, we observed the
counterfactual equivalent of the PTE obtained with conventional (linear or logistic) regression
techniques is the ratio E½10i  00i =E½11i  00i . The denominator is the diﬀerence in the logit of
the occurrence of fracture for individuals under BZA and placebo at their observed BMD values.
The numerator compares occurrence of fracture for individuals receiving the placebo, with BMD
values under BZA versus placebo. An alternative would be to compute PTE as the ratio
E½11i  01i =E½11i  00i . Here, the numerator compares the occurrence of fracture for individuals
under BZA, with BMD values under BZA versus placebo. The diﬀerence between both PTEs resides
in the interaction term between treatment and BMD (h5). In this study, BZA and BMD didn’t
Table 4. Direct and indirect effects of BZA on the logit of incident fractures in the 3 regions for total hip and neck
femoral BMD.
Region 1 Region 2 Region 3
Hip BMD
Direct () 1.10 (1.11)a 0.52 (0.40) 1.13 (0.57)
3.34 to 1.09b 1.32 to 0.27 2.32 to 0.07
Indirect (	) 0.56 (0.60) 0.37 (0.20) 0.07 (0.16)
1.78 to 0.64 0.78 to 0.01 0.39 to 0.26
Neck femoral BMD
Direct () 1.06 (1.30) 0.65 (0.50) 1.03 (0.59)
3.80 to 1.39 1.66 to 0.34 2.25 to 0.08
Indirect (	) 0.14 (0.66) 0.51 (0.26) 0.17 (0.20)
1.14 to 1.54 1.07 to 0.03 0.58 to 0.20
aMean (SD).
bLower and upper credibility interval.
BMD: bone mass density; BZA: bazedoxifene acetate.
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interact to cause fracture (95% credibility intervals for h5 include 0) so both PTEs were equivalent.
But it is not always the case and the choice between PTEs will depend upon the research
question.15,25
Eﬀects of BZA on incidence of fracture were diﬀerent across regions. In region 2, part of its
impact was via changes in BMD. In the other two regions, indirect eﬀects were not signiﬁcantly
diﬀerent from null (Table 4): BZA induced only direct eﬀects in region 3 while no eﬀects were found
in region 1. These diﬀerences between regions may be due to a combination of biological and socio-
economic factors that could have inﬂuenced diﬀerently individuals in the placebo and BZA
groups.36 Osteoporosis is indeed a multi-factorial disease, submitted to genetic and environmental
inﬂuences. Incidence of fracture in Canadian post-menopausal women has been associated with
dietary patterns.37 Variations in genes such as those involved in the RANK/RANKL/OPG
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Figure 2. Sensitivity analyses of the indirect effects for total hip (left panel) and femoral neck (right panel) BMD.
BMD: bone mass density.
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osteoporosis.38 Pharmacogenetics is another possible source of variation in individual responses to
BZA although, so far, no gene variations have been conclusively shown to be responsible for the
regulation of anti-osteoporosis drug response. Note, however, that most data on post-menopausal
women available in the literature has been obtained from Caucasian populations aged 65 or over,
and that information from other ethnic groups is limited.39
Finally, we considered whether unmeasured confounders may have introduced spurious
associations between BMD and incident fracture. Indeed, the assumption of sequential
ignorability was probably not met in this study because BMD slopes were observed after
participants were randomly allocated to placebo and BZA groups. The sensitivity analysis
showed that our estimates of indirect eﬀects were not very robust to violation of this assumption
(Figure 2). This highlights one important limitation of our work: our estimates are only valid in the
absence of post-treatment unmeasured variables that confound the relationships between BMD and
incident fracture. We hypothesize that estimates in previous studies with the same design were
sensitive to similar biases and may explain changeable results. Given the importance of the
matter, researchers are currently suggesting diﬀerent methods to estimate unmeasured
confounding, as recently reviewed.40
5 Conclusions
Our objective was to illustrate the use of piecewise regression, SEM and counterfactual to repeated
measurements of BMD from a study of BZA and vertebral fractures in three geographical regions.
We observed large individual variation in BMD temporal changes which suggests percent changes
from baseline up to a ﬁxed point in time may not be optimal in describing the non-linear trend in
BMD. Risk factors inﬂuenced directly or indirectly on one another: Baseline age and BMI
inﬂuenced baseline BMD that, in turn, had an eﬀect on the frequency of vertebral fractures.
Depending on the region, BZA acted either directly on the frequency of incident fractures or
indirectly through an eﬀect on BMD temporal changes (before the plateau). A causal
interpretation of the proportion of treatment explained is provided for one region: around 40%
of average diﬀerence in occurrence of fracture between BZA versus placebo individuals is due to
average diﬀerence observed for untreated individuals with BMD set at the value under BZA versus
under placebo. Estimates of indirect eﬀects can be biased in the presence of unmeasured post-
treatment variable. Fortunately, new research explores alternative statistical methods and
experimental designs to identify causal mediation eﬀects with weaker assumptions.
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